NEWS

Cardiola expands its strategic focus

Cardiola AG announced today that it is expanding the targeted patient population which may benefit from the Company’s CE-Marked m.pulse® Muscular Counter Pulsation (“MCP”)-based system. Previously, Cardiola was focused only on chronic heart failure patients at home. Now, the Company has expanded its focus to include acutely decompensated heart failure patients, with treatments offered exclusively in the clinic.
read more....

Clinical study demonstrates that Cardiola’s m.pulse^® system “immediately improves cardiac output under acute non-invasive Muscular CounterPulsation (MCP) treatment in patients with patients with stable CHF” (chronic heart failure)

Data presented at annual congress of the German Society of Cardiology (Apr. 23, 2010)
read more...

Cardiola collaborates with leading German cardiac center in study of its Muscular CounterPulsation (MCP)-based m.pulse^® system for non-surgically treating chronic heart failure patients at home

First 20 patients with early-stage (NYHA > II) CHF have been enrolled (Jan, 26.2010)
read more...

Cardiola raises $4 million from existing and new investors

“This funding milestone is dramatic validation that our m.pulse® system with Muscular CounterPulsation offers an entirely new paradigm for successfully treating Chronic Heart Failure,  non-surgically, in a patient’s home.” (Nov. 18.2009) 
read more...

Cardiola penetrates European market with its Muscular CounterPulsation (MCP)-based m.pulse^® system

Cardiola AG announced today that it has placed its patented m.pulse^® system in 10 hospitals located in Germany and Switzerland, on the heels of the system’s CE-Mark approval (Aug. 08, 2009)
read more...

Weitere Berichte finden Sie in unserem News Archiv